Trial intelligence / Profile preview

Personalized Kinase Inhibitor Therapy in Acute Leukemias

NCT02779283Phase 1Completed

Sponsor: OHSU Knight Cancer Institute
Start: Jan 2016
Primary completion: Apr 2018
Modality: Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
Countries: 1

Overview

Phase 1, open-label trial of sorafenib, sunitinib, dasatinib, ponatinib, ruxolitinib and 1 more in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of subjects who start a targeted drug at Day 8. Started Jan 2016; status: completed.

Drugs

sorafenibsunitinibdasatinibponatinibruxolitinib

Conditions

acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on NCT02779283.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02779283.